Welcome to our dedicated page for roivw news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on roivw stock.
Riovant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of medicines that matter. The company's pipeline includes VTAMA®, a topical treatment for psoriasis and atopic dermatitis, IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor in autoimmune indications, and brepocitinib, a small molecule inhibitor for dermatomyositis and non-infectious uveitis. Through creating nimble subsidiaries, Roivant aims to advance its therapies and technologies, while also nurturing discovery-stage companies and health tech startups.
Roivant (Nasdaq: ROIV) announced a live conference call and webcast scheduled for 8:00 a.m. ET on May 30, 2024, to discuss its fourth-quarter and fiscal year results ending March 31, 2024. The company will also provide a business update during this session. Investors can register online for the conference call. The presentation will be available under the 'Events & Presentations' section of Roivant’s website, where the archived webcast will also be accessible post-call.
FAQ
What is Roivant Sciences Ltd. focused on?
What are some products in Roivant Sciences Ltd.'s pipeline?
How does Roivant Sciences Ltd. advance its pipeline?
What additional initiatives does Roivant Sciences Ltd. undertake?